On May 25, in Prohost Letter Issue #421, we wrote about RegenxBio (RGNX), which from behind the scenes it created several gene therapy products that are being used by AveXis, a firm that was recently acquired by Novartis based on its successful pipeline products.
In the article (please read it if you missed it and read it again if you forgot it, or were not paying attention), we defined RegenxBio and its proprietary AAV gene delivery platform and the outstanding benefit gained from the use of this platform. We also . . .